BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCBB:BIOAF), a pioneering
biopharmaceutical company focused on overcoming the limitations of therapeutic
drug delivery across the blood-brain barrier, reported that new research
conducted under its BT2111 (Herceptin(R)) program shows that BT2111-a conjugate
of the metastatic cancer drug, Herceptin-not only crosses the blood-brain
barrier, but also penetrates the blood-tumor barrier up to 10 times better than
Herceptin alone.


BT2111 was developed by biOasis's drug delivery platform, Transcend, which
offers the creation of a new class of drugs that can cross the blood-brain
barrier to address unmet medical needs in the treatment of metastatic cancer, as
well as other brain diseases, like neurodegeneration and metabolic disease.


"Through image analysis and quantitative autoradiography in this animal study,
we've now demonstrated that BT2111 distributed evenly in healthy sections of the
brain, surrounded the metastatic brain cancer, and was present at significantly
greater levels within the tumors compared to equal to or lower dose equivalence
of Herceptin alone," said Rob Hutchison, CEO of biOasis Technologies. "This
observation corroborates the therapeutic responses seen in our prior animal
models."


"Treating cancer is extremely challenging as it is, but with brain tumors we
have the additional hurdles of the blood-brain and blood-tumor barriers,"
continued Hutchison. "Unfortunately, metastatic forms of brain cancer are even
more problematic. MedlinePlus has reported that for many people with metastatic
brain tumors the cancer is not curable. It will eventually spread to other areas
of the body, with death often occurring within two years. This grim statistic
has been a major compelling factor for us initiating the BT2111 program."


"Understanding the mechanisms of actions of BT2111 is pivotal in the development
of new therapeutic options for the treatment of HER2-positive metastatic brain
cancer and other forms of metastatic brain cancers," added Hutchison. "We are
continuing our BT2111 program at a number of locations."


In the treatment of brain tumors, drug delivery is complicated by the presence
of the blood- brain barrier (BBB). The variability of the BBB and heterogeneity
in permeability of the blood- tumour barrier (BTB) depends on tumor type, size,
location, and prior treatments. There is complexity in the tumor microvessel
populations (the brain-tumour barrier) that feed the growing metastatic cancer
cells in the brain. The BTB remains a significant impediment to the use of
standard chemotherapeutic delivery and efficacy in brain metastases of breast
cancer. Recent research with anti-angiogenic treatment demonstrated that
glioblastomas can continue to grow and even increase tissue invasion without the
need for a second wave of angiogenesis. These findings indicate that primary
brain tumors proliferate behind an intact BBB and that this barricade has to be
crossed by any drug aimed to affect tumor growth.


About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the company please visit www.bioasis.ca.


Herceptin(R) is a registered trademark of Genentech/Roche.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward- looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors

Rob Hutchison Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
778-383-3280
rob@bioasis.ca
www.bioasis.ca


Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Senior Managing Director
949-574-3860
BTI@liolios.com

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024